1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

A stable quarter with several news

MAR

1 Januay-31 March

  • Net sales reached SEK 4,6 (5,3) million
  • Loss after taxes SEK -2,1 (-1,2) million
  • Earnings per share were SEK -0,04 SEK (-0,03)
  • Cash and equivalents were 7,9 (5,6) million

Significant events during period

  • Utility patent for the Schelin Catheter was approved in China
  • Distribution agreement signed for the UK market
  • The Schelin Catheter™ used in conjunction with Water Vapor Therapy treatment for BPE
  • Agreement on a loan of SEK 5 million via ALMI and the three largest shareholders

Significant events after the end of the period

  • The new platform, CoreTherm® Eagle, submitted for CE marking
  • Agreement with Capio Specialistcenter. Order value SEK 2.4 million over a 12 month period.
Key figures



(SEK MILLION)jan-mar
2022		jan-mar
2021		jan-mar
2020		jan-mar
2019
Net sales4,65,34,63,6
Gross margin, %81837264
Operating profit/loss-2,1-1,2-1,6-2,8
Cash flow from operating activities-5,1-2,21,40,4
Average number of employees7756

” During the quarter, several strategically important pieces of the puzzle came into place for the company's continued growth in the future”

Johan Wennerholm
CEO, ProstaLund AB (publ)

Please see attached PDF for full report.

For further information, please contact:

Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-05 08:15 CEST.

Attachments

ProstaLund AB (publ) Delårsrapport Jan Mar 2022 05 03 ENG

Datum 2022-05-05, kl 08:15
Källa MFN
Bifogade filer
ProstaLund AB (publ) Delårsrapport Jan Mar 2022 05 03 ENG
Affiliate
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.